Glenmede Trust’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.8M | Sell |
72,854
-737
| -1% | -$139K | 0.06% | 269 |
|
|
2026
Q1 | $14.5M | Buy |
73,591
+1,336
| +2% | +$258K | 0.07% | 232 |
|
|
2025
Q4 | $13.3M | Buy |
+72,255
| New | +$12.7M | 0.06% | 268 |
|
|
2025
Q1 | $9.16M | Sell |
62,333
-545
| -0.9% | -$78.9K | 0.05% | 364 |
|
|
2024
Q4 | $8.24M | Sell |
62,878
-32,688
| -34% | -$4.58M | 0.04% | 368 |
|
|
2024
Q3 | $14.9M | Buy |
95,566
+3,404
| +4% | +$549K | 0.07% | 284 |
|
|
2024
Q2 | $14.4M | Sell |
92,162
-2,792
| -3% | -$420K | 0.07% | 279 |
|
|
2024
Q1 | $12.9M | Sell |
94,954
-7,398
| -7% | -$980K | 0.06% | 319 |
|
|
2023
Q4 | $13.8M | Sell |
102,352
-109
| -0.1% | -$14.2K | 0.07% | 284 |
|
|
2023
Q3 | $13.9M | Sell |
102,461
-22,198
| -18% | -$3.03M | 0.08% | 256 |
|
|
2023
Q2 | $17.3M | Hold |
124,659
| – | – | 0.1% | 219 |
|
|
2023
Q1 | $17.3M | Buy |
124,659
+4,301
| +4% | +$579K | 0.1% | 219 |
|
|
2022
Q4 | $16.3M | Buy |
120,358
+5,817
| +5% | +$729K | 0.1% | 234 |
|
|
2022
Q3 | $12.6M | Buy |
114,541
+10,359
| +10% | +$1.31M | 0.08% | 263 |
|
|
2022
Q2 | $13.8M | Buy |
104,182
+9,944
| +11% | +$1.3M | 0.08% | 275 |
|
|
2022
Q1 | $12.5M | Buy |
94,238
+2,614
| +3% | +$313K | 0.06% | 344 |
|
|
2021
Q4 | $10.7M | Sell |
91,624
-6,785
| -7% | -$798K | 0.05% | 365 |
|
|
2021
Q3 | $11.8M | Buy |
98,409
+7,317
| +8% | +$852K | 0.06% | 333 |
|
|
2021
Q2 | $10.9M | Sell |
91,092
-9,042
| -9% | -$992K | 0.06% | 338 |
|
|
2021
Q1 | $9.96M | Buy |
100,134
+29,039
| +41% | +$2.92M | 0.05% | 329 |
|
|
2020
Q4 | $7.11M | Buy |
71,095
+2,395
| +3% | +$254K | 0.04% | 360 |
|
|
2020
Q3 | $7.53M | Buy |
68,700
+784
| +1% | +$87.2K | 0.05% | 341 |
|
|
2020
Q2 | $7.18M | Sell |
67,916
-9,086
| -12% | -$938K | 0.04% | 343 |
|
|
2020
Q1 | $7.68M | Hold |
77,002
| – | – | 0.04% | 398 |
|
|
2019
Q4 | $7.68M | Buy |
77,002
+440
| +0.6% | +$41.4K | 0.04% | 398 |
|
|
2019
Q3 | $6.82M | Sell |
76,562
-4,769
| -6% | -$414K | 0.03% | 396 |
|
|
2019
Q2 | $6.71M | Sell |
81,331
-1,222
| -1% | -$95.8K | 0.03% | 421 |
|
|
2019
Q1 | $6.67M | Sell |
82,553
-4,898
| -6% | -$386K | 0.03% | 422 |
|
|
2018
Q4 | $6.64M | Sell |
87,451
-19,611
| -18% | -$1.53M | 0.03% | 410 |
|
|
2018
Q3 | $8.47M | Sell |
107,062
-2,275
| -2% | -$172K | 0.03% | 401 |
|
|
2018
Q2 | $7.68M | Sell |
109,337
-96,890
| -47% | -$6.97M | 0.03% | 398 |
|
|
2018
Q1 | $14.3M | Hold |
206,227
| – | – | 0.06% | 338 |
|
|
2017
Q4 | $14.3M | Buy |
206,227
+36,517
| +22% | +$2.46M | 0.06% | 338 |
|
|
2017
Q3 | $11.5M | Buy |
169,710
+20,638
| +14% | +$1.3M | 0.05% | 345 |
|
|
2017
Q2 | $9.28M | Hold |
149,072
| – | – | 0.04% | 373 |
|
|
2017
Q1 | $9.28M | Buy |
149,072
+6,370
| +4% | +$371K | 0.04% | 373 |
|
|
2016
Q4 | $7.8M | Buy |
142,702
+4,289
| +3% | +$244K | 0.04% | 392 |
|
|
2016
Q3 | $9.09M | Sell |
138,413
-1,731
| -1% | -$113K | 0.05% | 371 |
|
|
2016
Q2 | $8.46M | Sell |
140,144
-60,173
| -30% | -$3.5M | 0.05% | 373 |
|
|
2016
Q1 | $11.3M | Sell |
200,317
-98,028
| -33% | -$5.89M | 0.07% | 330 |
|
|
2015
Q4 | $20.3M | Sell |
298,345
-4,811
| -2% | -$315K | 0.14% | 247 |
|
|
2015
Q3 | $19.3M | Sell |
303,156
-447
| -0.1% | -$29.4K | 0.14% | 243 |
|
|
2015
Q2 | $19.3M | Sell |
303,603
-6,574
| -2% | -$450K | 0.14% | 243 |
|
|
2015
Q1 | $21.2M | Buy |
310,177
+8,820
| +3% | +$613K | 0.15% | 213 |
|
|
2014
Q4 | $21.2M | Sell |
301,357
-2,414
| -0.8% | -$173K | 0.17% | 190 |
|
|
2014
Q3 | $21.7M | Sell |
303,771
-13,223
| -4% | -$968K | 0.19% | 155 |
|
|
2014
Q2 | $23.6M | Sell |
316,994
-142,478
| -31% | -$10.3M | 0.21% | 112 |
|
|
2014
Q1 | $29.8M | Sell |
459,472
-58,149
| -11% | -$3.76M | 0.28% | 81 |
|
|
2013
Q4 | $30.7M | Buy |
517,621
+14,876
| +3% | +$808K | 0.31% | 64 |
|
|
2013
Q3 | $26.1M | Buy |
502,745
+45,563
| +10% | +$2.29M | 0.31% | 72 |
|
|
2013
Q2 | $21.6M | Buy |
+457,182
| New | +$23.3M | 0.27% | 80 |
|
Other funds holding AZN
EP
IA
Glenmede Trust's AZN Position: Q2 2026 in Review
Glenmede Trust reduced its AstraZeneca (AZN) stake by 1% in Q2 2026, selling an estimated $139K and leaving 72,854 shares worth $13.8M. The position accounts for 0.06% of the portfolio, ranked #269.
Glenmede Trust first reported a position in AZN in Q2 2013 and has held it in 51 quarters since. The position peaked at $30.7M in Q4 2013. 1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Glenmede Trust held 72,854 shares of AstraZeneca worth $13.8M as of Q2 2026.
- Glenmede Trust sold 737 AstraZeneca shares in Q2 2026, an estimated $139K.
- AstraZeneca made up 0.06% of Glenmede Trust's portfolio in Q2 2026, its #269 holding.
- Glenmede Trust first reported a position in AstraZeneca in Q2 2013 and has held it in 51 quarters since.
- Glenmede Trust's AstraZeneca position peaked at $30.7M in Q4 2013.
- 1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.